243 completed, 76 recruiting, 62 unknown, 58 active not recruiting. 528 Phase 3, 68 Phase 2.
Follow Neoplasms, Nerve Tissue: new trials by email Literature Review of Neoplasms, Nerve Tissue trials Research Report on Neoplasms, Nerve Tissue
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma Cerebraca wafer, Temozolomide (for relapsed malignant glioma) - Recurrent Glioblastoma, IDH-Wildtype | Phase 2 / Phase 3 | Not yet recruiting | Everfront Biotech Co., Ltd. | 175 | 2027-04-01 | 2026-09-10 |
| Safety and Efficacy Study of Safusidenib in Participants With Grade 2 IDH1-Mutant Glioma Safusidenib, Placebo - Grade 2 Glioma (Astrocytoma or Oligodendroglioma) With an IDH1 Mutation, Astrocytoma IDH Mutant Grade 2 | Phase 3 | Not yet recruiting | Nuvation Bio Inc. | 140 | 2027-03-01 | 2026-07-17 |
| Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma Bridging Chemotherapy, Induction Cycles A1-A3, Induction Cycles A4-5 - Medulloblastoma | Phase 3 | Not yet recruiting | Nationwide Children's Hospital | 96 | 2027-01-01 | 2026-10-20 |
| IMPT Versus IMRT for Diffuse Intrinsic Pontine Glioma Intensity-Modulated Proton Therapy (IMPT), Intensity-Modulated Radiation Therapy (IMRT) - Diffuse Intrinsic Pontine Gliomas (DIPG) | Phase 3 | Not yet recruiting | Shandong Cancer Hospital and Institute | 142 | 2026-12-01 | 2026-10-09 |
| PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma Chemical Exchange Saturation Transfer Magnetic Resonance Imaging, Contrast-enhanced Magnetic Resonance Imaging, Magnetic Resonance Imaging - Glioblastoma | Phase 3 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 60 | 2026-12-01 | 2026-07-07 |
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Intraoperative Ultrasound for Brain Tumor Surgery Enhanced by AI BrainUS-AI real-time intraoperative ultrasound segmentation system - Brain Tumor Adult | Phase 3 | Not yet recruiting | Hospital del Rio Hortega | 100 | 2026-12-01 | 2026-09-17 |
| Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms Somatostatin Analogue(s) - Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm | Phase 3 | Not yet recruiting | Washington University School of Medicine | 240 | 2026-11-30 | 2026-10-19 |
| SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years Semaglutide (Wegovy) weekly injection, Placebo weekly Injection - Craniopharyngioma, Child | Phase 3 | Not yet recruiting | University Hospital, Angers | 50 | 2026-11-01 | 2026-09-29 |
| Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma Tris-CAR-T cell injection, Ommaya reservoir implantation, Temozolomide (TMZ) - Newly Diagnosed Glioblastoma, IDH-wildtype | Phase 2 / Phase 3 | Not yet recruiting | Beijing Tiantan Hospital | 60 | 2026-10-15 | 2026-10-14 |
| Using an Artificial Intelligence (AI) Tool for Melanoma Diagnosis Clinical decision support tool - Malignant Melanoma of Skin, Other and Unspecified Malignant Neoplasm of Skin | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 14000 | 2026-10-15 | 2026-10-22 |
| Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma: MagMen-II Superparamagnetic Iron Oxide, Technetium (99mTc) - Melanoma (Skin Cancer) | Phase 3 | Not yet recruiting | Vastra Gotaland Region | 254 | 2026-10-01 | 2026-09-03 |
| ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma ZG005 for Injection, Etoposide Injection, Cisplatin Injection - Neuroendocrine Carcinomas (NEC) | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 440 | 2026-10-01 | 2026-09-22 |
| Clinical Benefit of 18F-FET in Glioma. 18F-Fluoroethyl-l-tyrosine - Glioma, 18F-Fluoroethyl-l-tyrosine | Phase 3 | Not yet recruiting | Primo Biotechnology Co., Ltd | 36 | 2026-10-01 | 2026-07-13 |
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma Darovasertib, Crizotinib (Xalkori) - Uveal Melanoma | Phase 3 | Recruiting | IDEAYA Biosciences | 450 | 2026-09-01 | 2026-09-15 |
| Temporally-Modulated Pulsed Radiation Therapy Versus Standard Radiation Therapy for the Treatment of Newly Diagnosed, IDH Wildtype, MGMT-Unmethylated Glioblastoma Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma | Phase 3 | Recruiting | NRG Oncology | 398 | 2026-07-16 | 2026-09-10 |
| A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma ZG006, 5-fluorouracil, Calcium folinate and Irinotecan - Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 240 | 2026-07-01 | 2026-05-19 |
| Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer Intensity-Modulated Radiation Therapy, Volume Modulated Arc Therapy, Pencil Beam Scanning - Astrocytoma, IDH-Mutant, Grade 3 | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 408 | 2026-06-24 | 2026-11-03 |
| Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma Adjuvant Therapy, Comprehensive Geriatric Assessment, Computed Tomography - Cutaneous Melanoma | Phase 3 | Recruiting | ECOG-ACRIN Cancer Research Group | 428 | 2026-04-17 | 2026-09-24 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
Showing 20 of 528. Sign in to see all of them.
Melanoma (181) · Glioblastoma (108) · Brain Neoplasms (54) · Glioma (51) · Astrocytoma (49) · Neuroblastoma (44) · Neoplasms (43) · Neuroendocrine Tumors (40) · Neoplasm Metastasis (29) · Central Nervous System Neoplasms (28) · Oligodendroglioma (23) · Sarcoma (23) · Gliosarcoma (21) · Uveal Melanoma (21) · Breast Neoplasms (19)
Neoplasms by Histologic Type (520) · Neoplasms, Germ Cell and Embryonal (502) · Neuroectodermal Tumors (502) · Neoplasms (485) · Neoplasms by Site (311) · Neoplasms, Glandular and Epithelial (276) · Neoplasms, Neuroepithelial (237) · Neuroendocrine Tumors (228) · Nevi and Melanomas (199) · Skin and Connective Tissue Diseases (193) · Skin Diseases (190) · Skin Neoplasms (166) · Glioma (128) · Nervous System Diseases (121)
Temozolomide (77) · Radiotherapy (64) · Carboplatin (40) · Vincristine (40) · Etoposide (36) · Nivolumab (36) · Cyclophosphamide (34) · Dacarbazine (31) · Lomustine (29) · pembrolizumab (28) · Doxorubicin (27) · Ipilimumab (27) · Cisplatin (26) · Filgrastim (20) · Magnetic Resonance Spectroscopy (20)
European Organisation for Research and Treatment of Cancer - EORTC (25) · National Cancer Institute (NCI) (21) · Bristol-Myers Squibb (20) · Children's Oncology Group (19) · Novartis Pharmaceuticals (13) · Merck Sharp & Dohme LLC (11) · Hoffmann-La Roche (9) · Sun Yat-sen University (9) · Alliance for Clinical Trials in Oncology (6) · Assistance Publique - Hôpitaux de Paris (6) · Cancer Research UK (6) · M.D. Anderson Cancer Center (6) · NRG Oncology (6) · Radiation Therapy Oncology Group (6) · Biocad (5)
United States (274) · Canada (164) · France (154) · Germany (148) · United Kingdom (144) · Italy (131) · Spain (125) · Australia (124) · Netherlands (119) · Belgium (100) · Switzerland (94) · Austria (78) · Poland (77) · Israel (70) · Sweden (66)
Matthew Krebs, Dr (5) · Roger Stupp, MD (5) · Alexander M. M. Eggermont, MD, PhD (3) · Lawrence E. Flaherty, MD (3) · William Shapiro, MD (3) · Alan W. Craft, MD (2)
PMID 32691060, PMID 34225229, PMID 36346112, PMID 36653848, PMID 39504507, PMID 19269895, PMID 20567002, PMID 21600759, PMID 23054107, PMID 23504141, PMID 25649350, PMID 25667295, PMID 26446943, PMID 27864013, PMID 28662232, PMID 29023494, PMID 30053159, PMID 31166680, PMID 31395089, PMID 32746839, PMID 33152282, PMID 35344750, PMID 35489301, PMID 35731991, PMID 36648215, PMID 40306120, PMID 41811823, PMID 10549493, PMID 10761648, PMID 10882162, PMID 11180089, PMID 11464889, PMID 11586105, PMID 11745440, PMID 12101494, PMID 12165894, PMID 12192533, PMID 12880954, PMID 12932669, PMID 14665609, PMID 15234047, PMID 15251162, PMID 15459300, PMID 15465203, PMID 15727424, PMID 15758009, PMID 15758010, PMID 15890570, PMID 16033132, PMID 16129365
U10CA180886 (14), U10CA098543 (12), 2023 (10), 2018 (8), U10CA180868 (7), 2008 (5), U10CA180820 (5), 2004 (4), 2009 (4), 2014 (4), 2015 (4), 2016 (4), U10CA032102 (4), 2019 (3), U10CA021115 (3)